Loading...
•
May 31, 2024
Accolade Q1 2025 Earnings Report
Accolade's physician-led advocacy approach increased accessibility to healthcare and improved outcomes.
Key Takeaways
Accolade announced financial results for the fiscal first quarter ended May 31, 2024, with a focus on profitable growth and positive Adjusted EBITDA.
Revenue increased by 18% year-over-year.
Net loss improved by 28% year-over-year.
Adjusted EBITDA improved by 73% year-over-year.
Adjusted Gross Profit increased by 30% year-over-year.
Forward Guidance
Accolade provides forward-looking guidance on revenue and Adjusted EBITDA.
Positive Outlook
- Revenue between $104 million and $106 million for the fiscal second quarter ending August 31, 2024.
- Adjusted EBITDA loss between $8 million and $10 million for the fiscal second quarter ending August 31, 2024.
- Revenue between $460 million and $475 million for the fiscal year ending February 28, 2025.
- Adjusted EBITDA between $15 million and $20 million for the fiscal year ending February 28, 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...